These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35920701)

  • 61. Development of bullous pemphigoid in a patient with psoriasis and metabolic syndrome.
    Lesniewska A; Kalińska-Bienias A; Kowalewski C; Schwartz R; Wozniak K
    Cutis; 2016 Sep; 98(3):E19-E23. PubMed ID: 27814422
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid.
    Iwata Y; Komura K; Kodera M; Usuda T; Yokoyama Y; Hara T; Muroi E; Ogawa F; Takenaka M; Sato S
    Arch Dermatol; 2008 Jan; 144(1):41-8. PubMed ID: 18209167
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
    Mai Y; Nishie W; Izumi K; Shimizu H
    Front Immunol; 2019; 10():1224. PubMed ID: 31191560
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.
    Veeravalli V; Dash RP; Thomas JA; Babu RJ; Madgula LMV; Srinivas NR
    Drug Saf; 2020 Aug; 43(8):711-725. PubMed ID: 32367507
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical and Immunological Profiles of 14 Patients With Bullous Pemphigoid Without IgG Autoantibodies to the BP180 NC16A Domain.
    Nakama K; Koga H; Ishii N; Ohata C; Hashimoto T; Nakama T
    JAMA Dermatol; 2018 Mar; 154(3):347-350. PubMed ID: 29299596
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles.
    Tanaka M; Hashimoto T; Dykes PJ; Nishikawa T
    Clin Exp Dermatol; 1996 Jan; 21(1):23-7. PubMed ID: 8689764
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Bullous pemphigoid of infancy - report and review of infantile and pediatric bullous pemphigoid.
    Ferreira BR; Vaz AS; Ramos L; Reis JP; Gonçalo M
    Dermatol Online J; 2017 Feb; 23(2):. PubMed ID: 28329498
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Coexistence of psoriasis vulgaris and vitiligo with bullous pemphigoid: a case report.
    Jankowski M; Czajkowski R; Scibior K; Schwartz RA
    Int J Dermatol; 2014 Jul; 53(7):e359-61. PubMed ID: 24134305
    [No Abstract]   [Full Text] [Related]  

  • 69. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid.
    Schmidt E; Obe K; Bröcker EB; Zillikens D
    Arch Dermatol; 2000 Feb; 136(2):174-8. PubMed ID: 10677092
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients.
    Di Zenzo G; Grosso F; Terracina M; Mariotti F; De Pità O; Owaribe K; Mastrogiacomo A; Sera F; Borradori L; Zambruno G
    J Invest Dermatol; 2004 Jan; 122(1):103-10. PubMed ID: 14962097
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Bullous pemphigoid of childhood: autoantibodies target the same epitopes within the NC16A domain of BP180 as autoantibodies in bullous pemphigoid of adulthood.
    Chimanovitch I; Hamm H; Georgi M; Kroiss M; Stolz W; Apitz C; Bröcker EB; Zillikens D
    Arch Dermatol; 2000 Apr; 136(4):527-32. PubMed ID: 10768652
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Biological predictors shared by dementia and bullous pemphigoid patients point out a cross-antigenicity between BP180/BP230 brain and skin isoforms.
    Julio TA; Vernal S; Massaro JD; Silva MC; Donadi EA; Moriguti JC; Roselino AM
    Immunol Res; 2018 Oct; 66(5):567-576. PubMed ID: 30220011
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Anti-p200 pemphigoid: Remission under mycophenolate mofetil (Cellcept®)].
    Raffin D; Delaplace M; Roussel A; Estève E
    Ann Dermatol Venereol; 2013 Dec; 140(12):784-7. PubMed ID: 24315224
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid.
    Feng S; Wu Q; Jin P; Lin L; Zhou W; Sang H; Shao C
    Int J Dermatol; 2008 Mar; 47(3):225-8. PubMed ID: 18289320
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Relapse-associated autoantibodies to BP180 in a patient with anti-p200 pemphigoid.
    Kasperkiewicz M; Hoppe U; Zillikens D; Schmidt E
    Clin Exp Dermatol; 2010 Aug; 35(6):614-7. PubMed ID: 19874345
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Coexisting bullous pemphigoid and psoriasis successfully treated with etanercept.
    Cusano F; Iannazzone SS; Riccio G; Piccirillo F
    Eur J Dermatol; 2010; 20(4):520. PubMed ID: 20403800
    [No Abstract]   [Full Text] [Related]  

  • 77. An evaluation of baricitinib as a therapeutic option for adult patients with moderate to severe atopic dermatitis.
    Mendes JT; Balogh EA; Strowd LC; Feldman SR
    Expert Opin Pharmacother; 2020 Jun; 21(9):1027-1033. PubMed ID: 32208940
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Coexistence of psoriasis and linear IgA bullous dermatosis.
    Takagi Y; Sawada S; Yamauchi M; Amagai M; Niimura M
    Br J Dermatol; 2000 Mar; 142(3):513-6. PubMed ID: 10735961
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effect of Baricitinib on TPA-induced psoriasis like skin inflammation.
    Hiraganahalli Bhaskarmurthy D; Evan Prince S
    Life Sci; 2021 Aug; 279():119655. PubMed ID: 34043988
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Non-Bullous Pemphigoid: A Single-Center Retrospective Study.
    Moar A; Azzolini A; Tessari G; Schena D; Girolomoni G
    Dermatology; 2021; 237(6):1039-1045. PubMed ID: 33979792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.